As of Aug 29
| -0.16 / -0.37%|
The 16 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 44.30, with a high estimate of 54.70 and a low estimate of 37.52. The median estimate represents a +3.19% increase from the last price of 42.93.
The current consensus among 16 polled investment analysts is to Hold stock in Novozymes A/S. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.